Scope of conference 鈥 2007 was a big year for both the implementation and recognition of the value of adaptive trial designs in drug development. This was evidenced by:
鈥 Large pharmaceutical organizations implementing and reporting time and cost savings associated with the use of adaptive trial designs
鈥 EMEA's finalization and publication of their "Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with Adaptive Design鈥 (CHMP/EWP/2459/02) last October
鈥 EMEA/EFPIA workshop on adaptive designs in confirmatory clinical trials conducted in Dec. 2007
www.healthtech.com
鈥 Large pharmaceutical organizations implementing and reporting time and cost savings associated with the use of adaptive trial designs
鈥 EMEA's finalization and publication of their "Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with Adaptive Design鈥 (CHMP/EWP/2459/02) last October
鈥 EMEA/EFPIA workshop on adaptive designs in confirmatory clinical trials conducted in Dec. 2007
www.healthtech.com